首页   >  
MAPK Pathway
  >  
Raf

所有产品分类

所有产品

信号通路

研究领域

天然产物

抗体

多肽

催化剂

杂质对照品

医药中间体

基础原料

Raf

结构式 货号 产品名称 CAS号
Exarafenib 结构式
 BCP49200 Exarafenib 2639957-39-2
Exarafenib is an antineoplastic. Exarafenib has anticancer activity by suppression of downstream MAPK pathway signaling.
Vemurafenib-Analog 结构式
 BCP27823 Vemurafenib-Analog 918505-61-0
Vemurafenib-Analog is a potent BRAF inhibitor and the isomer of Vemurafenib.
KG5 结构式
 BCP46930 KG5 877874-85-6
KG 5 is an orally available PDGFRß and B-Raf allosteric inhibitor.
Encorafenib 结构式
 BCP44104 Encorafenib 1269440-29-0
Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells.
Rineterkib hydrochloride 结构式
 BCP43938 Rineterkib hydrochloride 1715025-34-5
Rineterkib is a RAF and ERK1/2 inhibitor which has demonstrated preclinical activity in multiple MAPK activated cancer cells and xenograft models.
MCP110 结构式
 BCP43521 MCP110 521310-51-0
MCP110 is an inhibitor of Ras.
Vemurafenib 结构式
 BCP43160 维罗非尼 1029872-54-5
Vemurafenib is a selective inhibitor of BRAF kinase that is used in the therapy of patients with metastatic and advanced malignant melanoma. Vemurafenib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe cases of clinically apparent acute liver injury.
Lifirafenib 结构式
 BCP42783 Lifirafenib 1446090-79-4
Lifirafenib is a Novel potent and selective RAF Kinase and EGFR inhibitor.
Rineterkib 结构式
 BCP38204 Rineterkib 1715025-32-3
Rineterkib is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway.
Donafenib 结构式
 BCP34023 Donafenib 1130115-44-4
Donafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).
123下一页末页共 51 条记录 1 / 6 页 
2853530910